First-in-Human trial tests engineered immune cells against tough pancreatic cancer
NCT ID NCT06898385
Summary
This is an early-stage study to test the safety of a new treatment called IX001 TCR-T injection for people with advanced pancreatic cancer that has a specific genetic change (KRAS G12V mutation). The treatment involves collecting a patient's own immune cells, genetically modifying them in a lab to better target the cancer, and then infusing them back into the patient. The main goal is to see if this approach is safe and tolerable, while also checking for any early signs that it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.